Solís-Cabrera BH, Ramírez-Benítez MC, Cocotle-Ronzón Y, Moreno-Todd M, Soto-Cid AH

Language: Spanish
References: 19
Page: 25-28
PDF size: 30.42 Kb.

ABSTRACT

Objective: to evaluate urinary desoxypiridinoline (Dpd) levels in postmenopause patients, with osteoporosis or osteopenia after treatment with sodium alendronate.
Methods: a quasiexperimental study was carried out in 118 patients, aged from 41 to 69 years. According to the densitometry results and treatment received, we formed five groups: group I, patients with osteoporosis, treated with 10 mg/day of alendronate; group IIA, patients with osteopenia treated with alendronate 5 mg/day; group IIB, patients with osteopenia treated with hormonal therapy replacement (HTR); group IIIA, patients with normal densitometry treated with change of life style habits; and group IIIB, patients with normal densitometry treated with HTR. Dpd urinary levels were measured in all patients at the beginning and 60 days after. The statistical analysis was t Student paired.
Results: the group I diminished 7.8 nmol Dpd/mmol Cr with a p = 0.001. In the other groups the reduction of the urinary Dpd level was not significant.
Conclusions: in osteoporosis the urinary Dpd excretion diminishes after 60 days of treatment with 10 mg/day of sodium alendronate.

REFERENCES

1. Baluja CL, Brey Montoto CA, Baluja Conde IB. Marcadores bioquímicos asociados a la osteoporosis. Bioquimica 1998;23(1):788-793.

2. Silverman SL, Madison RE. Decreased incidence of hip fracture in Hispanics, Asians and Blacks: California Hospital Discharge Data. Am J Public Health 1988;78(11):1482-1483.

3. Murillo-Uribe A, Delezé-Hinojosa M, Aguirre E, Villa A, Calva J, Cons F, et al. Osteoporosis en la mujer posmenopáusica mexicana. Magnitud del problema. Estudio multicéntrico. Ginecol Obstet Mex 1999;67(5):227-233.

4. Morris HA, Wishart JM, Horowizt M, Need AG, Nordin BE. The reproducibility of bone-relate biochemical variables in post-menopausal women. Ann Clin Biochem 1990;27(PT 6):562-568.

5. Fleish H. Bone and mineral metabolism. En: Rubens RD, editor. Bisphosphonates in metastatic bone disease. Carnforth, England: Parthenon Publishing Group; 1995. p. 30.

6. Calvo MS, Eyre DR, Gundberg CM. Molecular basis and clinical application of biological markers of bone turnover. Endocr Rev 1996;17(4):333-368.

7. Ohishi T, Takahashi M, Kushida K, Yamazaki K, Hoshino H, Kitazawa A, et al. Urinary collagen cross-links reflect further bone loss of femoral neck in osteoporotic patients undergoing vitamin D therapy. Endocr Res 1998;24(2):259-267.

8. Cranney A, Guyatt, G, Griffith L, Wells G, Tugwell P, Rosen C. Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group Metaanalyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002;23(4):570-578.

9. Schnitzer T, Bone HG, Crepaldi G, Adami S, McClung M, Kield D, et al. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging Clin Exp Res 2000;12(1):1-12.

10. Chesnut CH III, McClung MR, Ensrud K. Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med 1995;99(2):144-152.

11. Prince RL, Smith M, Dick IM, Price RI, Webb PG, Henderson K, et al. Prevention of posmenopausal osteoporosis. A comparative study of exercise, calcium, supplementation, and hormone-replacement therapy. New Engl J Med 1991;325(17):1189-1195.

12. Garnero P, Shih WJ, Gineyts E, Karf DB, Delmas PD. Comparison of new biochemical markers of bone turnover in late posmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994;79(6);1693-1700.

13. Ogawa T, Ono T, Tsuda M, Kawanishi Y. A novel fluor in insoluble collagen: a cross-linking moiety in collagen molecule. Biochem Biophys Res Commun 1982;107(4):1252-1257.

14. Robins S, Woitge H, Hesley R, Ju J, Seyedin S, Seibel MA. Direct enzyme- linked inmunoassay for urinary deoxypyridinoline as a specific markers for measuring bone resorption. J Bones Miner Res 1994;9(10):1643-1649.

15. Robins S, Duncan A, Wilson N, Evans BJ. Standardization of pyridinium cross-links, pyridinoline and deoxypyridinoline, for use as biochemical markers of collagen degradation. Clin Chem 1996;42(10):1621-1626.

16. Orozco J, Morales G, Elizondo J. Estudio multicéntrico prevalencia de osteoporosis en México. 1995

17. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996; 348(9041):1535-1541.

18. Uebelhart D, Schlemmer A, Johansen J, Gineyst E, Christiansen C, Delemas P. Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links. J Clin Endocrinol Metab 1991;72(2):367-373.

19. Harris S, Gertz BJ, Genant HK, Eyre DR, Survill TT, Ventura JN, et al. The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early posmenopausal women. J Clin Endocrinol Metab 1993;76(6):1399-1406.